Policy pressure, affordability gaps, and consumer expectations are reshaping how pharma companies think about direct to ...

On this week's episode, Joel Latham, President and CEO at Incannex Healthcare, talks about developing cannabinoid and psychedelic combination therapies for conditions as diverse as sleep apnea, ...

Firm consolidation, thoughtful staffing, disciplined scope control, and performance accountability can save life sciences ...